CN106589062A - 靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用 - Google Patents
靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN106589062A CN106589062A CN201611128097.XA CN201611128097A CN106589062A CN 106589062 A CN106589062 A CN 106589062A CN 201611128097 A CN201611128097 A CN 201611128097A CN 106589062 A CN106589062 A CN 106589062A
- Authority
- CN
- China
- Prior art keywords
- covalent
- preparation
- grb2
- polypeptide
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 44
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 title claims abstract description 28
- 101150098203 grb2 gene Proteins 0.000 title claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 23
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 6
- 230000018883 protein targeting Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract description 32
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 27
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 5
- LRAMQBKQEYONOM-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(3-aminopropyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCCCN)C3=CC=CC=C3C2=C1 LRAMQBKQEYONOM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 150000001413 amino acids Chemical group 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 229940125808 covalent inhibitor Drugs 0.000 abstract description 2
- DBBFLHZBENZWFC-KRWDZBQOSA-N N[C@H](C(=O)O)CNC[ClH]CCCCCCCCCCCCCC Chemical group N[C@H](C(=O)O)CNC[ClH]CCCCCCCCCCCCCC DBBFLHZBENZWFC-KRWDZBQOSA-N 0.000 abstract 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 abstract 1
- 229940106681 chloroacetic acid Drugs 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 238000010189 synthetic method Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 24
- 238000000034 method Methods 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 4
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000009863 impact test Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 102000000395 SH3 domains Human genes 0.000 description 2
- 108050008861 SH3 domains Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000009465 prokaryotic expression Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000035183 Clathrin adaptor proteins Human genes 0.000 description 1
- 108091005769 Clathrin adaptor proteins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 102100022086 GRB2-related adapter protein 2 Human genes 0.000 description 1
- 102100033067 Growth factor receptor-bound protein 2 Human genes 0.000 description 1
- 108091009389 Growth factor receptor-bound protein 2 Proteins 0.000 description 1
- 101000900690 Homo sapiens GRB2-related adapter protein 2 Proteins 0.000 description 1
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101000900711 Mus musculus GRB2-related adaptor protein 2 Proteins 0.000 description 1
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 1
- ZMLRZBWCXPQADC-TUAOUCFPSA-N Pro-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 ZMLRZBWCXPQADC-TUAOUCFPSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 1
- 102000005588 Son of Sevenless Proteins Human genes 0.000 description 1
- 108010059447 Son of Sevenless Proteins Proteins 0.000 description 1
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611128097.XA CN106589062B (zh) | 2016-12-09 | 2016-12-09 | 靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611128097.XA CN106589062B (zh) | 2016-12-09 | 2016-12-09 | 靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106589062A true CN106589062A (zh) | 2017-04-26 |
CN106589062B CN106589062B (zh) | 2020-03-24 |
Family
ID=58598301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611128097.XA Active CN106589062B (zh) | 2016-12-09 | 2016-12-09 | 靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106589062B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108640974A (zh) * | 2018-05-19 | 2018-10-12 | 上海市第妇婴保健院 | 一种靶向作用Syntenin蛋白PDZ结构域的多肽及其二聚体 |
CN110669146A (zh) * | 2019-10-24 | 2020-01-10 | 常州大学 | 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003649A1 (en) * | 1994-07-22 | 1996-02-08 | The University Of North Carolina At Chapel Hill | Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME |
EP1281963A2 (en) * | 2001-07-30 | 2003-02-05 | Warner-Lambert Company | Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and a SH3 domain comprising peptide |
CN103387602A (zh) * | 2012-05-09 | 2013-11-13 | 中国科学院上海药物研究所 | 一种新型开链四肽类似物及其制备方法和用途 |
-
2016
- 2016-12-09 CN CN201611128097.XA patent/CN106589062B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003649A1 (en) * | 1994-07-22 | 1996-02-08 | The University Of North Carolina At Chapel Hill | Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME |
EP1281963A2 (en) * | 2001-07-30 | 2003-02-05 | Warner-Lambert Company | Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and a SH3 domain comprising peptide |
CN103387602A (zh) * | 2012-05-09 | 2013-11-13 | 中国科学院上海药物研究所 | 一种新型开链四肽类似物及其制备方法和用途 |
Non-Patent Citations (5)
Title |
---|
MICHEL VIDAL, ET AL.: "Molecular and Cellular Analysis of Grb2 SH3 Domain Mutants: Interaction with Sos and Dynamin", 《J. MOL. BIOL.》 * |
N. GOUDREAU,ET AL.: "NMR structure of the N-terminal SH3 domain of GRB2 and its complex with a praline-rich peptide from Sos", 《NATURE STRUCTURAL BIOLOGY》 * |
YONGSHENG YU,ET AL.: "Affinity-guided protein conjugation: the trilogy of covalent protein labeling, assembly and inhibition", 《SCI CHINA CHEM》 * |
YONGSHENG YU,ET AL.: "PDZ-Reactive Peptide Activates Ephrin‑B Reverse Signalingand Inhibits Neuronal Chemotaxis", 《ACS CHEM. BIOL》 * |
彭电等: "基于配体结构的Grb2-SH2抑制剂的结构优化更高的活性、更少的电荷、更低的肽性", 《有机化学》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108640974A (zh) * | 2018-05-19 | 2018-10-12 | 上海市第妇婴保健院 | 一种靶向作用Syntenin蛋白PDZ结构域的多肽及其二聚体 |
CN108640974B (zh) * | 2018-05-19 | 2021-07-06 | 上海市第一妇婴保健院 | 一种靶向作用Syntenin蛋白PDZ结构域的多肽及其二聚体 |
CN110669146A (zh) * | 2019-10-24 | 2020-01-10 | 常州大学 | 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽 |
CN110669146B (zh) * | 2019-10-24 | 2023-05-23 | 常州大学 | 一种可特异性阻断衔接蛋白Nck的结合位点用于预防肠道EPEC感染的活性肽 |
Also Published As
Publication number | Publication date |
---|---|
CN106589062B (zh) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9907857B2 (en) | Peptide having cell membrane penetrating activity | |
CN109328067A (zh) | 诱导程序性细胞死亡的cd47激动剂、及其治疗程序性细胞死亡缺陷相关疾病的用途 | |
RU2539832C2 (ru) | Пептиды цитоплазматического домена белка muc-1 в качестве ингибиторов раковых заболеваний | |
US9757473B2 (en) | Cell-penetrating peptide and conjugate comprising same | |
JP2008543961A5 (zh) | ||
CA2693651A1 (en) | Bioactive peptides and method of using same | |
US20230414702A1 (en) | Compounds and pharmaceutical use thereof in the treatment of cancer | |
CN104130315A (zh) | 一种特异靶向her2蛋白的多肽 | |
US20140322332A1 (en) | Antagonists of muc1 | |
WO2023165476A1 (zh) | 针对sort1的多肽化合物及其药物偶联物 | |
CN111690071A (zh) | 一种具有靶向穿膜性的抗肿瘤多肽 | |
CN106589062A (zh) | 靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用 | |
JP2010521441A5 (zh) | ||
CN107365361B (zh) | 与pd-l1结合的重复域锚定蛋白及其用途 | |
CN109157656B (zh) | 一种双靶标肿瘤疫苗及其制备方法和应用 | |
CN106699850A (zh) | Rbbp4靶向多肽和抗肿瘤多肽及其应用 | |
JP2019501964A (ja) | ポリペプチド化合物、並びにその調製方法及び適用 | |
CN108640973B (zh) | 一种靶向作用Syntenin蛋白的多肽及其二聚体和应用 | |
TW202019947A (zh) | 能夠刺激細胞激素釋放的新穎胜肽及其衍生物 | |
Yu et al. | Hydrocarbon stapling modification of peptide alyteserin‐2a: discovery of novel stapled peptide antitumor agents | |
CN106008673B (zh) | 一种基于nk3受体的合成肽nk3r-a1及其应用 | |
JP5924593B2 (ja) | 抗癌剤の活性増強剤 | |
CN116253774A (zh) | 一种tim-3亲和肽及其应用 | |
CN106008672B (zh) | 一种基于nk3受体的合成肽nk3r-a2及其应用 | |
Rai et al. | Synthesis, Characterization and Cytotoxicity of Short Cationic Lipopeptide Lp24 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240306 Address after: No. 144, Commercial Zone D, 20th Floor, North Tower of "Jiazhou Xixin Center", No. 59 Hongjin Avenue, Longxi Street, Yubei District, Chongqing, 401120 (Cluster Registration) Patentee after: Chongqing Hanqing Biotechnology Co.,Ltd. Country or region after: China Address before: No.536 Changle Road, Jing'an District, Shanghai 200040 Patentee before: SHANGHAI FIRST MATERNITY AND INFANT Hospital Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240313 Address after: Room 510-20, Building A, Advanced Ceramic Innovation Park, No. 125 Liuquan Road, High tech Zone, Zibo City, Shandong Province, 255000 Patentee after: Shandong Zaiying Health Industry Co.,Ltd. Country or region after: China Address before: No. 144, Commercial Zone D, 20th Floor, North Tower of "Jiazhou Xixin Center", No. 59 Hongjin Avenue, Longxi Street, Yubei District, Chongqing, 401120 (Cluster Registration) Patentee before: Chongqing Hanqing Biotechnology Co.,Ltd. Country or region before: China |